An opioid mixed agonist-antagonist analgesic, buprenorphine, significantly reduces cocaine self-administration by rhesus monkeys, but the relative contribution of buprenorphine's agonist and antagonist properties to this effect is unclear. This study examined the effects of concurrent treatment with naltrexone, a long-acting mu opioid antagonist, on buprenorphine's effects on cocaine and food self-administration by five rhesus monkeys. Cocaine (0.5 mglkg per injection) and food self-administration (1 gm banana pellet) were maintained on a second order fixed ratio 4 (FR4) variable ratio (VR) 16:5 schedule of reinforcement. Buprenorphine treatment alone (0.40 mglkglday) and in combination with ascending doses of naltrexone (0. OS, 0.10, 0.20, and DAD mglkglday) was compared with naltrexone alone (DAD mglkglday) and saline control treatment. Naltrexone was administered simultaneously or 20 minutes before buprenorphine administration. Each treatment condition was in effect for 10 days.
was substituted for buprenorphine, each monkey rapidly returned to its prebuprenorphine level of cocaine self administration. Food self-administration in all conditions was equivalent to or significantly higher (p < .05) than food-maintained responding during the saline baseline. When buprenorphine and naltrexone were administered simultaneously, naltrexone significantly attenuated buprenorphine's suppressive effects on cocaine self administration (p < .05 to .01). When naltrexone was administered 20 minutes before buprenorphine, there was a significant naltrexone dose-dependent (p < .01) decrease in buprenorphine's reduction of cocaine self administration in comparison to the initial saline baseline. These data suggest that naltrexone antagonizes the partial mu agonist component of buprenorphine, which may be important for buprenorphine's effects on cocaine self-administration. Moreover, the addition of an opioid antagonist to reduce illicit diversion of buprenorphine might also compromise its effectiveness for treatment of dual dependence on cocaine and opiates. [Neuropsychopharmacology 9:211-224, 1993J Buprenorphine, an opioid mixed agonist-antagonist an algesic, reduced cocaine self-administration by rhesus monkeys by 72% to 93% (Mello et al. 1989 (Mello et al. , 1990 ). This effect appeared to be selective for cocaine since food self-administration was initially reduced, but tolerance rapidly developed to buprenorphine's suppressive ef fects on food-maintained responding. In subsequent studies, we found that daily buprenorphine adminis tration selectively reduced cocaine self-administration for as long as 120 days (Mello et al. 1992a) . More re cently, we found that daily buprenorphine treatment decreased the reinforcing potency of cocaine in rhesus 0893-133X/93/$6 .00 monkey and shifted the cocaine dose-response curve approximately one half to 1 log unit to the right Lukas et al. 1993) . Acute administration of buprenorphine to rhesus monkey also reduced rates of cocaine-maintained responding and suppressed the peak response without altering its apparent potency (Winger et al. 1992) . Cocaine-base smoking by rhesus monkeys and cocaine self-administration by rats were also reduced by buprenorphine treatment Carroll and Lac 1992) . These preclinical data are concordant with clinical evaluations of buprenor phine's effects on cocaine abuse by polydrug abusers.
Buprenorphine was signiflcantly more effective than methadone in reducing cocaine self-administration by opiate abusers (Kosten et al. 1989a (Kosten et al. , 1989b Rosen and Kosten 1991) . Ongoing clinical trials indicate that buprenorphine also signiflcantly decreases cocaine abuse by men who are dually dependent on cocaine and heroin, according to DSM-III-R criteria (Gastfriend et al. 1992 (Gastfriend et al. , 1993a Mello and Mendelson 1993a, 1993b; .
Buprenorphine is usually classifled as a low-efficacy mu agonist and has a complex profIle of opioid partial agonist and antagonist activity (Jaffe and Martin 1990; Winger et al. 1992) . The relative contribution of bu prenorphine's agonist and antagonist properties to its effects on cocaine self-administration is unknown. The goal of this study was to determine if concurrent ad ministration of a mu opioid antagonist, naltrexone, would change buprenorphine's effects on cocaine self administration. Naltrexone was selected for study be cause it has a long duration of action comparable to that of buprenorphine (Lee et al. 1988 ; Lewis et al. 1983 ).
In clinical studies, naltrexone antagonized the effects of opiate agonists for 24 to 48 hours (Martin et al. 1973; Mello et al. 1981; Verebey et al. 1976) . In rhesus mon keys, naltrexone's apparent antagonist affinity for mu opioid receptors has been shown in operant behavioral studies (France et al. 1990; France and Woods 1989) .
If naltrexone reduced buprenorphine's effects on co caine self-administration, this would suggest that bu prenorphine's partial mu opioid agonist component is of critical importance in its interactions with cocaine.
Alternatively, the antagonist component of buprenor phine may be important for its reduction of cocaine self administration. Naltrexone, as well as buprenorphine, reduced cocaine self-administration by rhesus monkeys in our earlier studies (Mello et al. 1990 ). Naltrexone also was more effective than an opioid agonist, methadone, in reducing cocaine abuse by opiate-dependent patients (Kosten et al. 1989a; Rosen and Kosten 1991) . If the ad dition of naltrexone enhanced buprenorphine's effects on cocaine self-administration, this would suggest that buprenorphine's interactions with cocaine are mediated by opioid antagonist activity.
We are unaware of any previous studies of the effects of naltrexone and buprenorphine combinations NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.3 on cocaine self-administration. There has been some interest in adding naloxone to buprenorphine formu· lations to reduce the possibility of illicit diversion of buprenorphine (Preston et al. 1988; Weinhold et al 1992) . Combinations of buprenorphine (0.4 or 0.8 mg/70 kg) and naloxone (0.4 or 0.8 mg/70 kg) reduced the sub jective and physiologic effects of buprenorphine in men who were not opiate dependent (Strain et al. 1992 ).
Buprenorphine (0.4 mg/70 kg) in combination with 0.8 mg per 70 kg of naloxone was never identifled as an opiate (Strain et al. 1992 ). Yet, a lower dose of nalox· one (0.2 mg) did not compromise the analgesic effec· tiveness of 0.3 mg buprenorphine in patients with postoperative pain (Rolly et al. 1986 ). When naloxone (0.2 mg, SC) was given in combination with buprenor· phine (0.2 and 0.3 mg, SC) to methadone-maintained men (30 mg/day), the opioid abstinence signs induced were less severe than, but qualitatively similar to, those produced by naloxone alone (Preston et al. 1988) . De spite its antagonist properties, buprenorphine pro duced minimal signs of opioid abstinence in patients maintained on methadone (25 to 45 mg/day) (Jasinski et al. 1983 ) and was not consistently identifled as an agonist or an antagonist in patients maintained on 30 mg/day of methadone (Strain et al. 1992) . Because buprenorphine does not precipitate severe withdrawal, it appears to be useful for opiate detoxifIcation (Bickel et al. 1988; Kosten and Kleber 1988) .
The effects of buprenorphine-naloxone combina tions have been studied in rats and monkeys, and pre treatment with naloxone usually blocks buprenorphine's effects. In squirrel monkeys (Saimiri sciureus), simultane ous administration of naloxone (0.1 to 1.0 mg/kg, 1M) and buprenorphine (0.01 to 0.10 mg/kg) resulted in an attenuation of the decreased rates of food-maintained responding induced by buprenorphine alone (Dykstra 1983) . Naloxone (0.3 mg/kg) antagonism of buprenor phine's rate-reducing effects was equivalent when nal oxone was given simultaneously with or 15 minutes be fore buprenorphine administration (Dykstra 1983 ).
Simultaneous naloxone (1.0 mg/kg) and buprenorphine administration antagonized the discriminative stimu lus effects of buprenorphine in rats (Shannon et al. 1984) . Concurrent administration of naloxone (0.1 mg/kg and 1.0 mg/kg) also antagonized the rate-de creasing effects of buprenorphine (0.0001 to 0.1 mg/kg) on both punished and unpunished food-maintained re sponding in squirrel monkeys (DeRosett and Holtzman 1984) . In rhesus monkeys that were not opioid depen dent, combined administration of buprenorphine and naloxone maintained more avoidance-escape behavior than buprenorphine alone (Hoffmeister 1986 ).
In the present study, we compared the effects of simultaneous naltrexone and buprenorphine adminis tration with the effects of pretreatment with the same ascending doses of naltrexone given 20 minutes before buprenorphine administration. The potential clinical utility of a buprenorphine-naltrexone combination would be greatest in a simultaneous administration par adigm . However, the profIle of buprenorphine's recep tor binding in relation to its pharmacologic effects is not well understood and the kinetic and binding profIle of buprenorphine in the presence of naltrexone is un known. Buprenorphine's agonist and antagonist actions appear to have a bell-shaped dose-response curve on several measures (Cowan et al. 1977; Lizasoain et al. 1991; Pechnick et al. 1985) . Kinetic studies indicate that buprenorphine reaches peak plasma levels within 2 minutes after intravenous administration in man (Bul lingham et al. 1980) , within 2 to 5 minutes in baboon (Lloyd-Jones et al. 1980) , and rapidly reaches peak lev els in rodent and baboon brain within 10 to 15 minutes after administration (Holland et al. 1989; Shiue et al. 1991) . Brain uptake studies with tracer doses of a fluori nated analogue of naltrexone [6-deoxy-613-fluoronaltrex one; cyclofoxy 1 indicate that near maximal brain uptake occurs within 20 minutes after administration (Kawai et aI. 1990; Ostrowski et al. 1987; Sawada et al. 1991) .
We also studied the effects of naltrexone given 20 minutes before buprenorphine on cocaine and food maintained responding. The 20-minute naltrexone pre treatment procedure was used to ensure that naltrex one binding to the opiate receptors occurred before buprenorphine administration . We postulated that if buprenorphine's opioid agonist effects were important in reducing cocaine self-administration, the adminis tration of naltrexone 20 minutes before buprenorphine would antagonize the partial mu agonist activity of buprenorphine. Alternatively, if buprenorphine's an tagonist effects were important in reducing cocaine self administration, then simultaneous administration of naltrexone and buprenorphine might increase the an tagonist effect of these compounds.
The effects of naltrexone given after buprenorphine were not studied because it is well established that opi oid antagonists do not reverse buprenorphine's effects ifbuprenorphine is given frrst. For example, behavioral studies have shown that the discriminative stimulus effects of buprenorphine could not be reversed by naltrexone given 25 minutes after buprenorphine, but could be prevented by naltrexone pretreatment in pigeons (France et al. 1984) . Similarly, administration of naloxone after buprenorphine did not antagonize buprenorphine's effects in a discrimination paradigm (Shannon et al. 1984) or on an analgesia measure in rats (Cowan et al. 1977) . In clinical studies, naltrexone did not precipitate withdrawal signs or symptoms in bu prenorphine-maintained patients as it did in metha done-maintained patients (Kosten et al. 1990 ).
METHODS
Five rhesus monkeys (Macaca mulatta) [one female and four males 1 were studied. Subjects weighed from 6.9
Naltrexone, Buprenorphine and Cocaine 213 kg to 13.1 kg (average 10.3 ± 1.05 kg) and had a history of intravenous cocaine self-administration that averaged 599 days (range 44 to 1002 days) at the beginning of this study. Monkeys were maintained at ad libitum weight and given multiple vitamins, fresh fruit and vegetables, and Purina monkey chow to supplement a banana pel let diet. Food supplements were given between 5:00 PM and 5:30 PM. Water was continuously available. A 12-hour light-dark cycle was in effect from 7 AM to 7 PM, and the experimental chamber was dark during food and drug self-administration sessions.
Double-lumen silicone rubber catheters (inside di ameter 0.028 inches, outside diameter 0.080 inches) were surgically implanted to facilitate pretreatment with saline, naltrexone, and buprenorphine (alone or in com bination with naltrexone) and concurrent cocaine self administration. Catheters were implanted in the jugular or femoral vein and exited in the midscapular region. All surgical procedures were performed under aseptic conditions, and monkeys were anesthetized with ei ther pentobarbital (30 mg/kg, IV) or ketarnine (25 mg/kg, 1M). After surgery, monkeys were given 200,000 units of Combiotic Dihydrostreptomycin and Penicillin G in tramuscular every other day for a total of hve injections. The intravenous catheter was protected by a tether sys tem consisting of a custom-htted nylon vest connected to a flexible stainless-steel cable and fluid swivel (Spaulding Medical Products, Birmingham, AL). This flexible tether system permits monkeys to move freely. Catheter patency was evaluated periodically by ad ministration of a short-acting barbiturate, methohexi tal sodium (3 mg/kg, IV), through the catheter.
Animal maintenance and research was conducted in accordance with the guidelines provided by the Com mittee on Laboratory Animal Resources. The facility is licensed by the U.S. Department of Agriculture, and protocols were approved by the Institutional Animal Care and Use Committee. The health of the monkeys was periodically monitored by consultant veterinarians trained in primate medicine. Operant food and drug acquisition procedures provided an opportunity for en vironmental manipulation and enrichment (Line 1987; Line et al. 1989) . Monkeys had visual, auditory, and olfactory contact with other monkeys throughout the study.
Sequence of Treatment Conditions
Effects of Simultaneous Buprenorphine-Naltrexone Com binations on Cocaine and Food Self-Administration (Study J). The goal of this study was to examine the effects of concurrent treatment with buprenorphine and naltrexone on cocaine and food self-administration. Buprenorphine alone (0.40 mg/kg/day) and in combi nation with ascending doses of naltrexone (0.05, 0.10, 0.20, and 0.40 mg/kg/day) were compared with naltrex one alone (0.40 mg/kg/day) and saline control treat-ment. The sequence of pretreatment conditions was as follows: (1) saline alone, (2) buprenorphine alone, (3) saline alone, (4 to 7) four combinations of buprenor phine and naltrexone, and (8) naltrexone alone . Each of the eight treatment conditions was in effect for 10 days. This buprenorphine dose (0.40 mg/kg/day) was within the range of doses that signihcantly reduced co caine self-administration in our previous studies (Mello et al. 1989 (Mello et al. , 1990 (Mello et al. , 1992a .
Effects of Naltrexone Pretreatment on Buprenorphine's
Effects on Cocaine and Food Self-Administration (Study II). Subsequently, the same four ascending doses of naltrexone (0.05 to 0.40 mg/kg/day) were administered 20 minutes before buprenorphine (0.40 mg/kg/day) and followed by a saline-only control treatment. Each of these fIve treatment conditions was in effect for 10 days. The 20-minute naltrexone pretreatment interval was used to ensure that there was suffi cient time for naltrex one to bind to the opioid receptors before buprenor phine was administered (Kawai et al. 1990; Ostrowski et al. 1987; Sawada et al. 1991) . Each treatment condi tion was in effect for 10 days.
Administration of Buprenorphine, Naltrexone or Saline Solutions
In Study I, buprenorphine, naltrexone, and buprenor phine-naltrexone combinations or an equal volume of saline control solution was administered as a slow in jection between 9:30 and 10:30 AM. In Study II, ascend ing doses of naltrexone (0.05 to 0.40 mg/kg/day) were administered 20 minutes before buprenorphine (0.40 mg/kg/day) administration. Each solution was slowly injected at a rate of 1 mI of solution every 10 minutes over a 50-minute period and flushed through with ster ile saline in a volume that exceeded the estimated cath eter dead space. This buprenorphine, naltrexone, and saline administration procedure was identical to that used in each of our previous studies (Mello et al. 1989 (Mello et al. , 1990 (Mello et al. , 1992a . Each treatment solution was infused through the second lumen of the double-lumen cathe ter. Both catheter lumens remained patent throughout the study.
Operant Behavioral Procedures and Apparatus
Monkeys worked at an operant task for food and intra venous cocaine injections in a well-ventilated chamber equipped with an operant panel, a pellet feeder, and a water dispenser. Drug injections were delivered by a syringe pump in a single pulse that dispensed 0.1 mI of fluid over a 0.9-second period. The operation of the syringe pump (Model 981210; Harvard Apparatus, Inc., South Natick, MA) was audible to the monkey. Sched ules of reinforcement were programmed by custom-NEUROPSYCHOPHARMACOLOGY 1993 -VOL. 9, NO. l designed software and run on Apple IIGS microcom puters.
Cocaine self-administration was studied at the dose that maintained the highest response rates during train· ing. All monkeys self-administered 0.05 mg/kg per in· jection of cocaine throughout this study. Food (1 gm banana pellet) and cocaine (0 .05 mg/kg per injection) self-administration were maintained on a second-order schedule of reinforcement [&xed ratio 4 (FR 4) variable ratio (VR) 16:S]. An average of 16 responses on a VR 16 schedule produced a brief colored stimulus light (S+). However, a drug injection or a food pellet was delivered only after an FR 4 of the VR 16 response reo quirements had been completed; that is, each food pel· let or drug injection required an average of 64 responses. These procedures were identical to those previously used in our studies of daily buprenorphine treatment (Mello et al. 1989 (Mello et al. , 1990 (Mello et al. , 1992a .
The conditions of food and cocaine availability were each associated with a different colored stimulus light (S + ) projected on a translucent Plexiglas response key (2 inches in diameter) in the center of the operant panel. No stimulus lights (S + ) were illuminated during time· out periods (when responses had no programmed can· sequence). When a food pellet or drug injection was delivered, the appropriate colored stimulus light (S+) (red or green) was illuminated for 1 second on 3 circles (3/4 inches in diameter) located in a vertical column be low the response key. These I-second colored stimu· Ius light flashes (S + ) also signaled the completion of each successive component of the second-order sched· ule response requirement.
Each experimental day began at 9:00 AM and con sisted of four food and four drug availability sessions. Food sessions began at 11:00 AM, 3:00 PM, 7:00 PM, and 7:00 AM each day and drug sessions began 1 hour later at 12 noon, 4:00 PM, 8:00 PM, and 8:00 AM. Each food or drug session lasted for 1 hour or until 100 food pellets or 20 drug injections had been delivered. Cocaine in jections were limited to 80 per day to minimize the pos sibility of adverse drug effects. A time-out period when responses have no programmed consequences occurs between successive drug and food sessions.
Drug Solution Preparation
Buprenorphine. Buprenorphine hydrochloride was ob tained from the National Institute on Drug Abuse (NIDA). Buprenorphine was dissolved in sterile water at a concentration of 8.0 or 16.7 mg/ml. The stock solu tion was then &Iter sterilized using a 0.22-J,1 &Iter and stored in sterile, pyrogen-free vials. Solutions were checked daily to ensure that no precipitate had formed. Fresh solutions were prepared every 14 to 21 days. Doses were calculated on the basis of the monkeys' weights so that a fInal dilution of stock solution (with sterile saline for injection, U.S.P.) resulted in a daily infusion of each buprenorphine dose in a volume of 5.0 ml per infusion.
Naltrexone. Naltrexone was obtained from NIDA. 
RESULTS
Buprenorphine's Effects on Cocaine Self-Administration
Buprenorphine significantly reduced cocaine self-ad ministration in comparison to saline treatment (p < .01).
Group data for fIve monkeys are shown in Figure 1 .
During saline treatment, monkeys self-administered an average of 65.5 (± 5.8) cocaine injections per day. Co caine self-administration fell to 27.9 (± 7.6) injections per day during buprenorphine treatment and then returned to baseline levels of 62.3 (± 3.6) injections per day when saline treatment was resumed (Fig. 1, left panel). This rapid increase in cocaine self-administra tion probably reflects the relatively short duration of buprenorphine treatment, because recovery was slower after 30 to 120 days of buprenorphine treatment (Mello et al. 1990 (Mello et al. , 1992a . Cocaine self-administration data for the group (n = 5) expressed as percent change from the initial saline treatment baseline are shown in Figure 2 (left panel).
Simultaneous Naltrexone and Buprenorphine
Buprenorphine alone reduced cocaine self-adminis tration by 53% but ascending doses of naltrexone in combination with the same dose of buprenorphine re duced cocaine self-administration by only 30%, 30%, 23%, and 23%, respectively (Fig. 2, left 
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Effects of Naltrexone Pretreatment on Buprenorphine's Effects on Cocaine Self-Administration (Study II)
Administration of naltrexone 20 minutes before bupre norphine resulted in a signifIcant naltrexone dose dependent attenuation of buprenorphine's reduction of cocaine self-administration (p < .01). Cocaine self administration remained signifIcantly lower than the initial saline treatment baseline at naltrexone doses of 0.05 to 0.20 mg/kg/day in combination with buprenor phine (Fig. 1, right panel) . But at the highest dose of naltrexone (0.40 mg/kg/day) and buprenorphine, co caine self-administration was not signifIcantly lower than during the fIrst saline treatment baseline condi tion (Fig. 1) . Cocaine self-administration during the third saline treatment condition also did not differ signifIcantly from the initial saline baseline (Fig. 1) . In comparison to buprenorphine treatment alone (53% reduction), there was an orderly naltrexone dose dependent decrease in buprenorphine's reduction of cocaine self-administration from 42% to 31 % to 19% to 8%, respectively, below the saline treatment baseline. Cocaine self-administration was signifIcantly higher during treatment with naltrexone doses of 0.10, 0.20, and 0.40 mg/kg in combination with buprenorphine than during buprenorphine alone (p < .05 to .01) (Fig.  2, right panel) . Cocaine self-administration during pretreatment with the lowest dose of naltrexone plus buprenorphine did not differ from buprenorphine alone (Fig. 2, right panel) .
Buprenorphine's Effects on Food Self-Administration
Food self-administration decreased from 91.7 ± 14 to 67.2 ± 9 pellets per day during buprenorphine treat· ment, but this change (26.7%) was not statistically signifIcant. When saline was substituted for buprenor· phine, food self-administration returned to control lev els of 95.7 ± 11 pellets per day. Food self-administration during saline and buprenorphine treatment is shown in Figure 3 or buprenorphine treatment alone. Food self-adminis tration was somewhat variable during this condition and showed no orderly relation to the ascending doses of naltrexone. Group data (n = 5) are shown in the cen ter panel of Figure 3 .
Effects of Naltrexone Pretreatment on Buprenorphine's Effects on Food Self-Administration (Study II)
Food self-administration did not differ signifIcantly from the saline treatment baseline throughout the 20-minute naltrexone pretreatment plus buprenorphine condition (Fig. 3, right panel) . However, there was a naltrexone dose-dependent increase in food self administration that paralleled the increase in cocaine self-administration (Figs. 1 and 3, right panels) . When cocaine self-administration increased further during the final saline treatment condition (Fig. 1) , food self administration returned to initial saline treatment lev els (Fig. 3) .
Individual Patterns of Cocaine Self-Administration During Buprenorphine and Naltrexone Treatment
Daily cocaine self-administration by individual mon keys during treatment with buprenorphine only, naltrexone only, and simultaneous administration of buprenorphine and naltrexone (0.40 mg/kg/day) are shown in figure 4. Data are shown as percent change from each monkey's saline treatment baseline to facili tate comparisons between subjects. The time course and degree of reduction in cocaine-maintained re sponding varied across individuals. Buprenorphine treatment was followed by an abrupt and sustained reduction in cocaine self-administration in four mon keys (Fig. 4, rows 1 to 4) . Over the 10 days of buprenor phine treatment, their cocaine self-administration was reduced by an average of 96%, 75%, 42%, and 35%, respectively. One monkey was relatively insensitive to buprenorphine treatment, and cocaine self-administra tion averaged only 20% below baseline (Fig. 4, row 5) .
In contrast to buprenorphine, naltrexone alone re- duced cocaine self-administration by an average of 25% in only one monkey (Fig. 4, row 2) . The other four monkeys' cocaine self-administration remained simi lar to their respective saline baselines during naltrex one treatment (range 7% to 10% below baseline). When the same doses of naltrexone and buprenor phine were administered simultaneously, cocaine self-administration was lower than during naltrexone treatment alone but higher than during buprenor phine treatment alone in all monkeys (Fig. 4 , rows 1 to 4) . The average reduction in cocaine self-adminis tration over 10 days from the previous saline treatment baseline ranged from less than 1% (Fig. 4 , row 3) to 59% (Fig. 4, row 2) . The effectiveness of the buprenor phine-naltrexone combination in reducing cocaine self-administration increased over time in three mon keys (Fig. 4 , rows 1, 2, and 4) and remained relatively stable in two monkeys (Fig. 4 , rows 3 and 5).
DISCUSSION
Effects of Buprenorphine and Buprenorphine-N altrexone Combinations on Cocaine Self-Administration
Buprenorphine alone (0.40 mg/kg/day) signifIcantly reduced cocaine self-administration by rhesus monkeys by an average of 53% in comparison to saline con trol treatment (p < 0.1). These data confrrm and extend previous fmdings in the primate and rodent drug self administration model Carroll and Lac 1992; Mello et al . 1989 Mello et al . , 1990 Mello et al . , 1992a . However, concurrent administration of naltrexone and bupre norphine signifIcantly reduced the effects of bupre norphine alone on cocaine self-administration ( Figs. 1  and 2 ) . Simultaneous administration of ascending doses of naltrexone (0.05 to 0.40 mg/kg/day) signifI cantly reduced the suppressive effects of buprenor phine treatment on cocaine self-administration (p < .05
to .01), but this effect was equivalent across the nal trexone doses studied. Naltrexone alone had no effect on cocaine-maintained responding. When naltrexone was given 20 minutes before buprenorphine, there was a significant naltrexone dose-dependent attenua tion of buprenorphine's effects on cocaine self-admini stration (p < .05 to .01) (Figs. 1 and 2 ). Because the opioid antagonist, naltrexone, has selective activity at the mu receptor (France et al. 1990; Martin et al. 1973 ) and buprenorphine is a partial mu agonist (Jaffe and Martin, 1990) , these data suggest that naltrexone antagonized the mu agonist compo nent of buprenorphine and this, in turn, attenuated buprenorphine's effectiveness in reducing cocaine self-administration in monkey. These data are consis- Consecutive Days tent with recent fmdings that naltrexone (0.3 to 1.0 mg/kg) antagonized the protective effects of bupre norphine in reducing lethality associated with cocaine induced convulsions in mice (Witkin et al. 1991) . The opioid agonists, morphine and methadone, also re duced cocaine-related lethality in mice, whereas naltrexone alone did not (Witkin et al. 1991) . These data were interpreted to suggest that buprenorphine's protective effects were mediated by mu opioid recep tors (Witkin et al. 1991) .
In rhesus monkey, acute administration of either an opioid agonist, (heroin, 0.03 and 0.10 mg/kg) or buprenorphine (1.0 and 3.2 mg/kg) suppressed rates of cocaine-maintained responding over the dose range of 0.001 to 0.1 mg/kg per injection of cocaine (Winger et al. 1992) . These data could be interpreted to suggest that buprenorphine was acting like a mu agonist in that paradigm. Yet, quadazocine, an opioid antago nist, produced equivalent suppression of cocaine maintained responding at doses of 0.1 and 1.0 mg/kg, which was interpreted as probably not due to its opi oid antagonist actions (Winger et al. 1992) . Because the effects of heroin, buprenorphine, and quadazocine on concurrent food-maintained responding were not studied by Winger and coworkers, the selectivity of these drug effects for cocaine cannot be established with certainty.
If the mu opioid agonist component of buprenor phine is one important factor in its interactions with cocaine, then treatment with an opioid agonist such as methadone should also be effective in reducing co caine self-administration. However, clinical reports indicate that methadone was less effective than buprenorphine or naltrexone in reducing cocaine abuse by opiate-dependent patients (Kosten et aI. 1989a (Kosten et aI. , 1989b . In other studies of opiate-dependent patients, intermittent cocaine use continued during treatment with either methadone or buprenorphine (Fudala et al. 1991; Johnson et al. 1992) . Moreover, co caine's acute subjective effects and heart rate increases were greater in polydrug users on methadone main tenance (50 mg/day) than in abstinent opioid abusers (Preston et al. 1993) . Preclinical studies of the effects of opioid agonists on cocaine self-administration by monkeys are also inconsistent; both no effect (Stretch 1977) and decreased cocaine self-administration have been reported (Wilson and Schuster 1970; Winger et al. 1992) .
Whatever the role of mu opioid agonist activity in buprenorphine-cocaine interactions, there is increas ing evidence that cocaine per se directly affects mu opioid receptors in the brain . Chronic cocaine ex posure increases opiate receptor density in rodent brain (Hammer 1989; Ishizuka et al. 1988; Unterwald et al. 1992) . Increased opiate receptor density in brain areas associated with drug reinforcement was inferred NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.3 from observed changes in binding of [3H]naloxone (Hammer 1989; Ishizuka et al. 1988 ) and a mu-selective opioid ligand [3H]DSAMGO (Unterwald et al. 1992 ). Evidence of cocaine-induced increases in opioid recep tor density in brain raises the intriguing possibility that the duration of cocaine exposure and/or the degree of cocaine dependence may influence buprenor phine's effectiveness in reducing cocaine self-admin istration. This notion is supported by the fmding that although buprenorphine (4 mg/day) signmcantly re duced cocaine self-administration by patients who met DSM-III-R criteria for dependence on cocaine as well as opiates and had abused both drugs for over 10 years (Gastfriend et al. 1992 (Gastfriend et al. , 1993a , both buprenorphine and methadone were equally ineffec tive in reducing cocaine intake in nondependent, in termittent cocaine abusers (Fudala et al. 1991; Johnson et al. 1992) . Because cocaine's reinforcing and discrim inative stimulus properties appear to reflect inhibition of dopamine reuptake (Johanson and Fischman 1989; Kuhar et al. 1988 ), buprenorphine's interactions with both endogenous opioid and dopaminergic systems are probably important for its effects on cocaine self administration. It was neuroendocrine evidence of dop amine-opioid interactions that originally prompted us to explore buprenorphine's effects on cocaine self-ad ministration (Mello and Mendelson 1993a, 1993b; Mello et al. 1989) . The complexity of these interactions is il lustrated by reports that buprenorphine increases dop amine release in rat nucleus accumbens (Brown et aI. 1991) and naltrexone (1.0 mg/kg) pretreatment pre vents buprenorphine (0.1 mg/kg) induced dopamine release in the nucleus accumbens (Holman et al. 1993 ).
Effects of Naltrexone on Cocaine and Food Self-Administration
The failure of naltrexone (0.40 mg/kg) alone to aff ect cocaine self-administration is not consistent with previous clinical reports (Kosten et al. 1989a) or with our previous studies in rhesus monkey (Mello et aI. 1990 ) . Naltrexone signifIcantly reduced cocaine-posi tive urines in heroin-dependent polydrug abusers (Kosten et al. 1989a ) and reduced cocaine self administration by rhesus monkeys by 25% to 27% (Mello et al. 1990 ) . Our previous studies were con ducted under identical behavioral conditions, and the doses of naltrexone (0.32 to 3.20 mg/kg/day) over lapped the dose used in the present study (0.40 mg/kg/day) (Mello et al. 1990 ). However, monkeys had a different sequence of exposure to treatment con ditions. In our previous studies, naltrexone was ad ministered after 15 days of saline treatment (Mello et al. 1990 ), whereas in this study, naltrexone treatment followed 40 days of treatment with buprenorphine and naltrexone combinations. Only one monkey (199C) was a subject in both studies. Naltrexone (0.32 mg /kg/day) significantly decreased cocaine self administration (p < .01) after 10 days of treatment (dur ing days 11 to 15) in this monkey in our previous study (Mello et al. 1990 ), but cocaine self-administration was minimally affected by naltrexone (0.40 mg/kg/day) in the present study (see Fig. 4 ). The difference in naltrexone's effects in our two studies may be at tributable, in part, to persistent effects of buprenor phine after 40 days of exposure. These data also under score the importance of drug history and behavioral history in influencing responsivity to naltrexone (War ren and Morse 1989).
Naltrexone did not change food-maintained re sponding in comparison to the initial saline treatment baseline (Fig. 3) . Naltrexone pretreatment was fol lowed by a dose-dependent increase in food self administration that paralleled an increase in cocaine maintained responding (Figs. 1 and 3 ). In contrast to previous studies in squirrel monkeys (Goldberg et al. 1981) , there was no evidence of excessive salivation or vomiting during 10 days of naltrexone treatment or 40 days of combined naltrexone and buprenorphine treatment in the present study or in our previous studies (Mello et al. 1990 ). In squirrel monkey, acute naltrexone administration (10 mg/kg) produced saliva tion and vomiting and after chronic daily naltrexone treatment for 38 to 39 days, supersensitivity to nal trexone developed and a lower dose (0.3 mg/kg) also produced vomiting (Goldberg et al. 1981) . These dis crepant fIndings may reflect diff erences in the naltrex one doses studied (10 mg/kg vs. 0.40 mg/kg) as well as unexplained species diff erences .
Buprenorphine-Cocaine Interactions
We have suggested that buprenorphine's unique com bination of agonist and antagonist characteristics is essential for its selective effects on cocaine self administration Mello and Mendel son 1993a, 1993b) . Other opioid mixed agonist-antag onist analgesics such as nalbuphine and butorphanol also produce dose-dependent decreases in cocaine self-administration by rhesus monkeys Winger et al. 1992) . However, these effects of chronic butorphanol and nalbuphine treatment over 10 days were not selective for cocaine because food maintained responding also decreased in parallel with cocaine self-administration .
Although data described in this study suggest that the mu agonist component of buprenorphine is impor tant for its interactions with cocaine, the mechanisms by which buprenorphine reduces cocaine self-admin istration are unknown. There is also compelling be havioral and physiologic evidence that buprenorphine has kappa antagonist effects in addition to its partial Naltrexone, Buprenorphine and Cocaine 221 mu agonist properties. In behavioral studies, bupre norphine antagonized the effects of a selective kappa agonist, U50,488 (Negus and Dykstra 1988; Negus et al. 1990 Negus et al. , 1991 . Buprenorphine also precipitated with drawal in kappa agonist-dependent monkeys (Gmerek et al. 1987) and antagonized the diuretic effects of a kappa agonist, bremazocine (Leander 1987; Richards and Sadee 1985) . The extent to which buprenorphine's kappa antagonist effects may also contribute to its sup pressive effects on cocaine self-administration re mains to be determined once systemically active selec tive kappa antagonists become available .
Clinical Implications
Because the simultaneous administration of buprenor phine and naltrexone significantly reduced the sup pression of cocaine self-administration achieved with buprenorphine alone (Figs . 1 and 2 ), the addition of an opioid antagonist to reduce illicit diversion of bupre norphine might compromise its effectiveness for treat ment of cocaine and opiate dependence. The extent to which these fIndings with naltrexone, a long-acting mu opioid antagonist, are applicable to naloxone, a short acting mu opioid antagonist is unknown. Naloxone buprenorphine combinations attenuated the subjective and physiologic effects of buprenorphine alone but did not compromise buprenorphine's analgesic effec tiveness in persons who were not opiate-dependent (Strain et al. 1992; Rolly et al. 1986 ) . In methadone dependent men, naloxone-buprenorphine combina tions induced abstinence signs similar to the effects of naloxone alone (Preston et al. 1988) . In preclinical stud ies, naloxone pretreatment antagonized buprenor phine's effects on a variety of behavioral measures (Dykstra, 1983; Shannon et al. 1984; DeRosett and Holtzman, 1984) . There is considerable clinical evi dence that buprenorphine reduces cocaine abuse in opiate-dependent patients (Kosten et al. 1989; Rosen and Kosten 1991) as well as in polydrug abusers depen dent on both cocaine and opiates (Gastfriend et al. 1992 (Gastfriend et al. , 1993a . The concordance between preclin ical and ongoing clinical evaluations of buprenorphine treatment suggests the value of animal models of drug self-administration for predicting the effectiveness of new pharmacotherapies for drug abuse treatment Mello, 1992) .
